Leveraging their expertise in covalent binding chemistry, Biomea Fusion has built a proprietary platform called FUSION™ System to advance a pipeline of novel covalent therapies. Their lead product candidate, BMF-219, is a potent and selective covalent inhibitor of MENIN, a transcriptional regulator involved in oncogenic signaling. Biomea Fusion aims to become a leader in developing covalent small molecules to maximize clinical benefit in treating various cancers.